3 weeks ago

Molbio Diagnostics IPO Subscribed 4.39 Times on Final Day

Molbio Diagnostics IPO Subscribed 4.39 Times on Final Day
Molbio Diagnostics IPO Day 3: Issue subscribed 4.39 times so far. Here's GMP, size, & other details - Apply or not? · livemint.com

Molbio Diagnostics makes a small machine called Truenat that helps doctors find diseases quickly, even in places without big laboratories.

The machine runs on batteries and can give test results in about an hour.

The company wants to grow, so it is selling parts of itself to the public for the first time, which is called an IPO.

People can buy shares for between ₹768 and ₹807 each.

By the last day of the sale, investors had asked for more than four times as many shares as the company was offering.

The company's own employees were very interested, and big-money investors asked for more than nine times the shares set aside for them.

Unofficial 'grey market' traders think the shares might be worth about ₹945 when they start trading.

Some experts say buying the shares is good for patient, long-term investors, while one firm warns the price is already fully paid for.

The money raised will help expand the company's factories in Goa and Visakhapatnam.

The shares are expected to start trading on August 17.

Key facts

Company
Molbio Diagnostics Ltd (founded October 2000)
IPO price band
₹768–₹807 per share
Issue size
~₹939.70 crore (₹200 crore fresh issue + ₹739.70 crore OFS)
Final-day subscription
4.39 times (as of 10:35 am on August 12, 2026)
Grey market premium
~₹138 per share (≈17.10% over upper price band)
Estimated listing price
~₹945 per share
Anchor investment
₹281.5 crore from 33 anchor investors at ₹807 per share
Listing date
August 17, 2026 (NSE and BSE); allotment expected August 13

Quotes

Swastika Investmart

Swastika Investmart brokerage analyst

“"The company’s valuation is broadly in line with industry levels and remains below the average P/E multiple of 64.9x for its listed peers."”
livemint.com
“"We believe the issue is fully priced and recommend a "Subscribe – Long Term" rating to the IPO."”
livemint.com

Sources

Related news